- 肿瘤微小环境 -
Currently there is huge excitement about the tumour microenvironment. Investigators are discovering the many mechanisms used by the tumour to defend itself from immune attack from the host. These mechanisms are on the tumour surface and in the stromal microenvironment. This track on Targeting the Tumour Microenvironment presents extraordinary findings that increase our understanding of cancer, and investigations to overcome these barriers. We will present promising results in vitro, in vivo and in the clinic.


Preliminary Agenda


Plenary Keynote Session

Moderator's Opening Remarks

Janine Schuurman, PhD, Corporate Vice President, Research & Innovation, Genmab BV

Bicycles and Bicycle Drug Conjugates

Sir Gregory Winter, PhD, FRS, Master, Trinity College; Co-Founder and Director, Bicycle Therapeutics

Using Protein Engineering to Make Therapeutics in Situ

Andreas G. Plückthun, PhD, Professor and Director, Department of Biochemistry, University of Zürich

TARGETING MYELOID CELLS TO OVERCOME IMMUNO-SUPPRESSION

KEYNOTE: Myeloid Cells in Tumor Microenvironment: Targeting Opportunities.
Dmitry Gabrilovich, MD, PhD, Professor, Immunology, Microenvironment and Metastasis, The Wistar Institute

Manipulation of Myeloid Cells for Optimal Antibody Immunotherapy
Mark Cragg, PhD, Professor, Experimental Cancer Biology, Antibody & Vaccine Group, University of Southampton

IgA as a Novel Isotype to Treat Cancer, and Enhancement by Targeting Neutrophil Checkpoint Inhibitors
Jeanette Leusen, PhD, Associate Professor, Translational Immunology, University Medical Center Utrecht

Breaking the Truce between Macrophages and Cancer in Order to Conquer Solid Tumors
Marie Kosco-Vilbois, PhD, CSO, Novimmune SA

NOVEL APPROACHES TO TARGET THE TUMOUR STROMA

Novel Approaches to Target the Tumor Stroma for Cancer Immunotherapy
Christian Klein, PhD,Distinguished Scientist, Head, Oncology Programs, Cancer Immunotherapy Discovery, PRED, Roche Innovation Center Zurich

Impact of Cytokine Fusion Proteins Delivered to the Tumour Microenvironment
Dario Neri, PhD, Professor, Biomacrolecules, Chemistry and Applied Biosciences, ETH Zürich

Selective IL-2 Immunotherapy to Fuel the Anti-Tumor T Cell Response
Onur Boyman, MD, Professor and Chair, Clinical Immunology, University of Zurich

IMPACT OF ONCOLYTIC VIRUSES AND VECTOR VACCINES ON IMMUNE MODULATION

Studies with Oncolytic Viruses and Vector Vaccines and Immune-Modulation: The Yin and the Yang
Philipp Müller, PhD, Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG

Targeting Immunotherapy to the Tumour Microenvironment Using Bispecific Antibodies
Len Seymour, PhD, Professor, Gene Therapy, University of Oxford

CHECKPOINT INHIBITORS, FC RECEPTORS AND ANTAGONISTS

Update on Studies on Checkpoint Inhibitors and Fc Receptors
Frederick Arce Vargas, MD, PhD, MRCS, Research Associate, UCL Cancer Institute

TNFR2 Antagonists for Immunotherapy with No Risk of Autoimmunity in Mouse Models and Human Trails
Denise L. Faustman, MD, PhD, Director, Immunobiology, Massachusetts General Hospital, and Associate Professor, Medicine, Harvard Medical School

ADVANCES IN THE CLINIC

Clinical Advances with Entinostat HDAC Inhibitors in Metastatic Breast Cancer
Michael Myers, PhD, CMO, Syndax Pharmaceuticals, Inc.


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English